Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 16, 2016 - Issue 3
Submit an article Journal homepage
287
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy

J GaultneyMapi Group, Houten, NetherlandsCorrespondence[email protected]
,
M BenucciOspedale S.Giovanni di Dio Firenze, Florence, Italy
,
S IannazzoSIHS Health Economics Consulting, Turin, Italy
,
C NappiBristol-Myers Squibb, Rome, Italy
,
K SionMapi Group, Houten, Netherlands
&
FJ SabaterBristol-Myers Squibb, Madrid, Spain
Pages 409-417 | Published online: 23 Oct 2015

References

  • Scott DL, Steer S. The course of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):943–967.
  • Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108.
  • Lapadula G, Ferraccioli GF. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S102–S106.
  • Leardini G, Salaffi F, Montanelli R, et al. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol. 2002;20(4):505–515.
  • Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–639.
  • Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
  • Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94.
  • Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324.
  • Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954–960.
  • IM101235. A randomized, head-to-head, single-blind study to compare the efficacy and safety of subcutaneous abatacept versus subcutaneous adalimumab, both with background methotrexate, in biologic-naive subjects with rheumatoid rrthritis. Data on file. 2013.
  • Compendio Farmaceutico Telematico-Banca dati del Farmaco di Farmadati Italia. 2014.
  • Official Gazette of the Italian Medicines Agency (AIFA). Ex-Factory Price net of GVT measures as AIFA Determination of 03.07.2006 and 27.09.2006. 2014.
  • Ministero della Salute. Tariffe delle prestazioni di assistenza specialistica ambulatoriale. Gazzetta Ufficiale della Repubblica Italiana. Serie N.23; Supplemento N.8 del 28 gennaio 2013.
  • Ministero della Salute. Tariffe delle prestazioni di assistenza ospedaliera per acuti. Gazzetta Ufficiale della Repubblica Italiana. Serie N.23; Supplemento N.8 del 28 gennaio 2013.
  • Smitten AL, Simon TA, Hochberg MC, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.
  • Della Rossa A, Neri R, Talarico R, et al. Diagnosis and referral of rheumatoid arthritis by primary care physician: results of a pilot study on the city of Pisa, Italy. Clin Rheumatol. 2010;29(1):71–81.
  • Benucci M, Cammelli E, Manfredi M, et al. Early rheumatoid arthritis in Italy: study of incidence based on a two-level strategy in a sub-area of Florence (Scandicci-Le Signe). Rheumatol Int. 2008;28(8):777–781.
  • Resident population at 1 January 2014. Italian National Institute of Statistics [L ‘Istituto Nazionale di Statistica].
  • Kobelt G, Kasteng F. Access to innovative treatments in rheumatoid arthritis in Europe. A report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA). 2009. Available from: http://www.lif.se/cs/Publik%20webb/Sidinnehall/Publik_Dokument/Pressmeddelanden/Access%20to%20RA%20Treatments%20October%202009.pdf
  • Benucci M, Saviola G, Manfredi M, et al. Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature. Int J Rheumatol. 2011. Epub 2011 Nov 9. DOI:10.1155/2011/845496.
  • Furneri G, Mantovani LG, Belisari A, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S72–S84.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.